Jasper reports positive ETESIAN asthma data; BEACON investigation clears drug product

Jasper Therapeutics, Inc.

Single 180mg briquilimab reduced sputum eosinophils from 10.3% to 2.32% at 6 weeks post-allergen challenge.
Late asthmatic response FEV1 AUC improved 25.4% at 6 weeks and 23.3% at 12 weeks vs baseline.
BEACON investigation: no drug product issues; 9 of 10 US patients likely did not have mast cell-driven CSU.
Briquilimab well-tolerated; no dose-limiting toxicities; safety profile consistent with prior studies.
Final BEACON data expected Q1 2026; Phase 2b CSU study planned to start mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.